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In the present work we identified B-cell epitopes recognized by sera of humans and rodents naturally infected with Andes virus, a
hantavirus present in Chile and Argentina. Analysis of patient and rodent sera with overlapping peptides revealed 21 human and rodent
epitopes on the three structural proteins. Whereas in the nucleoprotein the region comprising aa 248–260 was shown to be the key
determinant of human sera, the major antigenic site of rodent antibody reactivity is located at aa 326–338. In G1, the main epitope recognized
by human sera was mapped to aa 14–26, while rodent antibodies bound predominantly to aa 599–611. In contrast, humans and mice had
strong responses to three regions in G2 (aa 691–703, aa 918–930, aa 955–967), of which the last two are associated with neutralization of
Hantaan virus. This insight affords important information for the development of immunotherapies for the acute phase of hantavirus
cardiopulmonary syndrome.
D 2005 Elsevier Inc. All rights reserved.
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Hantaviruses form enveloped, spherical virions of 80–
140 nm in size. Like all members of the Bunyaviridae
family they possess three structural proteins: the glycopro-
teins 1 and 2 (G1 and G2), which are inserted into the viral
envelope membrane, and the nucleocapsid protein (N),
associated to the viral genomic ssRNA(). In humans they
cause two severe and often fatal diseases: hemorrhagic fever
with renal syndrome (HFRS) and hantavirus cardiopulmo-
nary syndrome (HCPS). The transmission to man of these
rodent borne diseases has been associated with inhalation of
aerosols from excreta of infected mice (Nuzum et al., 1988).
In Argentina and Chile approximately 1000 cases of HCPS,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: nicole.tischler@bionova.cl (N.D. Tischler).reaching mortality rates up to 40%, have been detected since
1993, when the new hantavirus variant named Andes
(ANDV) was first identified as the responsible etiological
agent (Lo´pez et al., 1996).
The ANDV has called attention by several particular
features. It is the only one known for which evidence of inter-
human transmission has been reported (Padula et al., 1998).
In addition, together with one other South American
hantavirus (Maporal virus) it is known to produce a fatal
disease in Syrian hamsters (Hooper et al., 2001; Milazzo et
al., 2002). Lastly, it has been detected in various rodent
species, supporting the idea that one virus species may infect
more than one rodent species (Jay et al., 1997; Kuenzi et al.,
1999; Morzunov et al., 1998; Plyusnin andMorzunov, 2001).
The principal reservoir of ANDV is Oligoryzomys long-
icaudatus (Levis et al., 1998); however, it also has been
detected with lower incidence in Abrothrix longipilis,
Abrothrix olivaceus, Phyllotis darwini, and Loxodontomys05) 319–326
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zomys chacoensis and Akodon varius in Argentina (Calderon
et al., 1999). The mechanism by which hantaviruses persist in
their natural reservoirs has been suggested to arise by escape
of specific CD8+ immune surveillance (Araki et al., 2004). In
contrast, humoral immune responses appear to be important
in conferring protection against viral infection (Arikawa et
al., 1992; Zhang et al., 1989). In persistently infected mice,
the observed strong neutralizing antibody responses (Botten
et al., 2003; Kariwa et al., 1996; Lee et al., 1981) may be
essential to suppress hantavirus dissemination and conse-
quently to avoid fatal illness (Araki et al., 2004). In
accordance with the former, HCPS patients with high
neutralizing antibody titers in the acute phase of infection
undergo a more favorable clinical outcome than patients with
lower titers (Bharadwaj et al., 2000, Galeno et al., unpub-
lished data). Hantavirus neutralizing activity has been related
to antibodies directed to the surface proteins, since mono-
clonal antibodies to G1 and G2, but not to N, have been
shown to neutralize viral infection in vitro (Dantas et al.,
1986). Hantavirus infections induce antibodies predomi-
nantly to N, followed by the G proteins (Kallio-Kokko et al.,
2001; Sjo¨lander et al., 1993). B-cell epitopes involved in
neutralization of Hantaan (HTNV) and Puumala virus
(PUUV) have been studied using neutralizing monoclonal
antibodies (Ho¨rling and Lundkvist, 1997; Koch et al., 2003;
Liang et al., 2003; Wang et al., 1993), while still no data is
available about the clearance of HCPS causing viruses.Table 1
Characterization of HCPS patient sera samples




1 2000-7367 M 30 4 Severe
2 2000-640 M 48 4 Severe
3 2001-4741 M 47 5 Severe
4 2001-5457 F 55 4 Severe
5 2001-1133 F 26 6 Severe
6 2001-4890 M 34 8 Moderat
7 2001-2725 M 23 6 Moderat
8 2001-2235 F 42 7 Mild
9 1997-703327 n.i. n.i. N90 n.i.
10 2001-4723 M 48 5 Mild
11 2001-3970 M 40 5 Severe
12 2001-1977 M 24 7 Severe
13 2000-6895 M n.i. 5 Severe
14 2001-645 M 32 10 Moderat
15 2000-3500 M 49 7 Moderat
16 2001-11629 M 26 9 Moderat
17 2001-1981 M 17 6 Mild
18 2001-2840 M 26 6 Moderat
19 2001-9423 F 19 210 n.i.
20 1997-703328 n.i. n.i. N90 n.i.
21 1997-703329 n.i. n.i. N90 n.i.
22 2000-9844 M 34 2 Moderat
23 2000-11457 F 33 21 Mild
Titers are reciprocal of dilutions. N = Hantavirus nucleoprotein; M = Male; F =
a Day in which sample was taken counted from the beginning of symptoms.
b 80% focus reduction.For the development of immunotherapies for HCPS
patients, it is important to understand the humoral immune
responses of infected humans and infected rodents. For this
aim here we investigate differences of humoral immune
responses between ANDV-infected humans and rodents and
between patients with different clinical outcomes. We
performed a fine mapping of B-cell epitopes on the three
structural proteins of ANDV recognized by sera of infected
individuals and compared them with their clinical evolution
and neutralizing antibody titers. Our results show the
existence of two immunodominant regions in G2 common
among human and rodent immune responses, while the
major antigenic domains in N and G1 differ between man
and mice. In contrast, no significant epitopic variations
could be distinguished related to the different clinical
outcomes of patients or neutralizing antibody titers. Never-
theless, among the 13 predominant epitopes identified on
the glycoproteins, five are homologous to regions in HTNV
or PUUV, which have been associated by others with viral
neutralization.Results and discussion
Characterization of immune sera
Sera of 23 HCPS patients with different clinical out-
comes were collected between days 2 and 210 after thee of Egress Titer of IgM Titer of IgG Neutralizing
anti N anti N Ab titerb
Deceased 6400 400 50
Deceased 6400 0 100
Survived 1600 800 100
Survived 6400 0 200
Survived 6400 0 200
e Survived 6400 0 200
e Survived 6400 400 200
Survived 6400 1600 200
Survived 400 400 200
Survived 6400 1600 300
Survived 6400 0 400
Survived 1600 0 400
Survived 6400 6400 400
e Survived 6400 400 400
e Survived 6400 1600 400
e Survived 6400 6400 800
Survived 6400 0 800
e Survived 6400 0 1600
Survived 0 6400 1600
Survived 1600 1600 1600
Survived 0 6400 2500
e Survived 6400 0 3200
Survived 6400 6400 3200
Female; n.i. = no information.
Fig. 1. Identification of ANDV nucleocapsid protein B-cell epitopes
recognized by human and rodent sera. Immune sera were incubated with 36
13-mer peptides covering the entire nucleocapsid protein (first column aa
1–428) and reactivity was detected with a chemiluminescence substrate.
White squares indicate no reactivity (grade 0), gray squares moderate
reactivity (grade 1), and black squares strong reactivity (grade 2) of human
(column no. 1–23) and rodent (column no. 24–30) immune sera. Human
sera (No. 1–23) are displayed from the lowest to the highest neutralizing
antibody titers, as seen with more detail in Table 1.
N.D. Tischler et al. / Virology 334 (2005) 319–326 321onset of symptoms. As seen in Table 1, the patients’ ages
ranged between 17 and 55 years (average of 34 years). The
majority of the patients were of male gender (15 of 23
patients). Table 1 also shows the clinical characteristics of
the patients, including serological information such as the
titer of N-specific IgG and IgM examined by ELISA and the
neutralizing antibody titer determined by focus reduction
neutralization assays. Of these sera, 21 contained N-specific
IgM, while 14 contained N-specific IgG, indicating that the
majority were derived from patients in the acute phase of
disease, while only two sera were from patients in the
convalescence phase. Furthermore, 21 samples derived from
surviving patients, while two were from deceased patients.
Notably, the deceased patients and most of the severe
patients show very low neutralizing antibody titers, suggest-
ing, as reported previously (Bharadwaj et al., 2000, Galeno
et al., unpublished data), their importance in the outcome of
HCPS. However, due to the small number of patients
examined and the lack of information of the clinical
outcome in five cases, no clear dependence could be
deduced. Rodent blood samples were also analyzed. The
samples were derived from ANDV-infected animals cap-
tured in Chile, six were from O. longicaudatus and one
from A. longipilis. All rodent samples studied contained N-
specific IgG (data not shown).
Human and rodent nucleocapsid protein B-cell epitopes
HCPS patient sera (n = 23) and sera from naturally
infected rodents (n = 7) were analyzed for reactivities
against 36 13-mer peptides of the nucleocapsid protein of
ANDV CHI-7913 (Tischler et al., 2003). As can be seen in
Fig. 1, epitopes recognized by the majority of human
immune sera could be located within seven regions
distributed over the entire N (aa 1–78, aa 144–169, aa
209–221, aa 248–260, aa 326–338, aa 365–377, aa 404–
428). Control sera as well as the detection antibody alone
showed no binding (data not shown). Of these seven
immunogenic regions, the epitope aa 248–260 located in
the middle region of the protein, could be identified as a
major antigenic domain since all of the 23 patient sera
reacted strongly with this peptide (average score = 1.8). In
contrast, rodent immune sera did not react with this region.
Instead, the region of aa 326–338 was found to be the major
rodent epitope on N (average score = 1.9) (Fig. 1). The
remaining reactivity patterns described for humans were
also shared by rodents, except the C terminal region aa 404–
428. In addition, a slight reactivity of rodent sera could be
detected at aa 183–195. Further immunoreactive regions
may exist within N, since the peptides were designed in a
non-overlapping manner.
Human and rodent glycoprotein B-cell epitopes
To identify B-cell epitopes of ANDV glycoproteins 1 and
2, we first examined the reactivity of four patient sera with87 non-overlapping 13-mer peptides, which represent the
entire ANDV CHI-7913 glycoprotein precursor (GPC)
sequence (Tischler et al., 2003). Subsequently a finer
mapping of the recognized areas was performed with 43
additional 13-mer peptides overlapping 6–7 amino acids.
No reactivity was detected from sera of uninfected humans
and rodents (data not shown).
Fig. 2A shows the results obtained with the 75 13-mer
peptides spanning the entire G1 (GPC aa 1–650). Six
immunoreactive human epitopes were identified with the 23
patient sera (aa 14–32, aa 46–58, aa 66–104, aa 189–201, aa
215–234, aa 300–344). Only three of these were also
recognized by sera of infected rodents (aa 46–58, aa 215–
234, aa 300–344), while rodent immune sera also reacted
with three other regions (aa 404–416, aa 521–533, aa 599–
611). As expected, all epitopes recognized by human sera
are located in the predicted ectodomain of this membrane
protein. In contrast, two of the three exclusive rodent
epitopes (aa 521–546, aa 599–611) are positioned in the
predicted cytoplasmatic tail of G1.
Of the epitopes identified in G1, the region of aa 14–26
presented the strongest reactivity with the majority of
human sera (average score = 1.5). Given that the glyco-
Fig. 2. Identification of ANDV glycoprotein B-cell epitopes of human and
rodent sera. Immune sera were incubated with 130 overlapping 13-mer
peptides comprising the entire G1 (A) and G2 (B) proteins (first columns aa
1–1138) and reactivity was detected with a chemiluminescence substrate.
White squares indicate no reactivity (grade 0), gray squares indicate
moderate reactivity (grade 1), and black squares strong reactivity (grade 2)
of human (column no. 1–23) and rodent (column no. 24–30) immune sera.
Human sera (No. 1–23) are displayed from the lowest to the highest
neutralizing antibody titers, as seen with more detail in Table 1. Squares
with horizontal lines indicate predicted transmembrane regions, and squares
with dots indicate predicted signal peptides.
Fig. 2 (continued).
N.D. Tischler et al. / Virology 334 (2005) 319–326322proteins of hantaviruses seem to be type 1 oriented
membrane proteins (Lo¨ber et al., 2001), a signal peptide
of about 20 aa length at their amino domain is probably
removed. This is supported by a sequencing study, in which
the amino terminus of mature G1 of HTNV virus was
shown to start at position 18 (Schmaljohn et al., 1987).
Therefore, the strong reactivity found in the region of aa 14–
26 could represent a linear epitope located at the amino
terminus of mature G1, freely accessible to B-cell receptor
and antibody binding. In contrast, there was no reactivity of
rodent sera to this area. A possible explanation might be that
in rodents the G1 protein is processed by different proteases
or may be the result of a different immune-repertoire
between humans and these particular strains of mice.
The results of our epitope studies of ANDV G1 are
consistent with HTNV epitopes recognized by mouse
monoclonal antibodies (Wang et al., 1993). As seen in
Fig. 3, three identified ANDV G1 epitopes correlate with
epitopes of neutralizing monoclonal antibodies against
Fig. 3. Comparison of G1 epitopes of ANDV and HTNV. Epitopes recognized by ANDV immune sera are underlined and regions recognized by monoclonal
antibodies against the HTNV G1 protein are marked by bold underlined letters and the corresponding antibody denomination is indicated below.
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epitopes of non-neutralizing antibodies against HTNV G1
(10F11, 6D4, 8B6) have all been localized in the amino
terminal region (aa 163–220) of G1. In this area, we
identified a human epitope (189–201) with different grades
of reactivity (grades 0 to 2), shown to be recognized in a
lesser degree by sera of patients with high neutralizing
antibody titers (N1:1600). Although only some of the
ANDV G1 epitopes comprise conserved regions within
hantaviruses, the strong correlation between epitopes of
HTNV and ANDV G1 proteins might reflect a similar
accessibility of these regions due to a similar conformation
of these envelope proteins. These results suggest that the
immunoreactive sites on G1 involved in HTNV neutraliza-
tion might also be relevant in the neutralization of ANDV.
Fig. 2B shows the results obtained with the 55 13-mer
peptides spanning the entire G2 (GPC aa 652–1138). Three
major immunogenic regions could be defined by human and
rodent immune sera in this protein: aa 678–703, aa 918–
930, and aa 955–967. Of these epitopes, the first is located
close to the amino terminal of mature G2. Within this
region, sera of infected individuals recognized strongly the
peptide aa 691–703 (average score of humans is 1.5 and of
mice 1.7) and to a lesser degree the peptide aa 678–690
(average score of humans is 0.7 and of mice 1.4), but the
majority did not react with the overlapping peptide aa 684–
696, suggesting the involvement of two independent
epitopes in this region.
In comparison, the very strong recognition of the region
aa 955–967 by human and mice sera (20 of 23 human sera
with grade 2; average score = 1.8 and 5 of 7 mice sera
with grade 2; average score = 1.7) emphasizes the
immunodominant role of this epitope within G2. This
region shows 91% similarity (76% identity) with the
homologous region of HTNV and is reported to be one ofFig. 4. Comparison of G2 epitopes of ANDV, PUUV, and HTNV. Epitopes re
neutralizing monoclonal antibody 1C9 and 4G2 against PUUV G2 protein and PUU
human recombinant neutralizing Fab fragments anti-HTNV G2 protein are marketwo core domains of recognition of a recombinant human
neutralizing antibody against the G2 protein of HTNV
(Koch et al., 2003) (see Fig. 4). Next to this epitope, the
region aa 918–930 also shows a strong B-cell response
with human (average score = 1.2) and mice sera (average
score = 1.6). This epitope is homologous to a region in
HTNV described to be the other core domain recognized
by a human neutralizing antibody against HTNV G2
(Koch et al., 2003) (see Fig. 4). Unlike the described
HTNV G2 epitope KVMATIDSF (aa 916–924), the
sequence recognized by sera of ANDV-infected individuals
seems to involve additional amino acids at its C-terminal
region for antibody binding, as sera reacted strongly with
the peptide RMMATKDSFQSFN (aa 918–930), but in
most cases not with the sequence SGYKRMMATKDSF
(aa 914–926) (Fig. 2B). The similarity in this region
between the ANDV and HTNV sequences amounts to 91%
(Fig. 4) compared with 77% of the overall similarity
between both G2 proteins. Additional data support the idea
that these two highly antigenic regions might be immuno-
dominant also in other hantavirus variants. These sites are
located in close vicinity to epitopes of PUUV-neutralizing
monoclonal antibodies 1C9 and 4G2 (aa 900–908; aa 913–
916, and aa 937 in the ANDV sequence) and of PUUV
patient sera (aa 939–959 in the ANDV sequence),
identified by neutralizing antibody escape mutants of
PUUV (Ho¨rling and Lundkvist, 1997) and phage displayed
peptides (Heiskanen et al., 1999), respectively (Fig. 4).
Given that the recombinant human neutralizing anti-
bodies against HTNV G2 also neutralize Seoul and Dobrava
virus (Koch et al., 2003), and since the epitopes of
neutralizing antibodies directed against PUUV G2 are
located in close vicinity, it is quite probable that the two
C-terminal major antigenic regions in ANDV G2 identified
here might also be involved in the neutralization of ANDV.cognized by ANDV immune sera are underlined, epitopes recognized by
V immune sera S1b and S3b are indicated by cursive underlined letters, and
d by bold underlined letters.
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show that sera from ANDV-infected humans recognize at
least ten highly reactive B-cell epitopes in G1 and G2 (see
Fig. 2 and Table 2), in comparison with the single epitope
described for the recombinant G proteins of the closely
related Sin Nombre virus (Jenison et al., 1994). Further-
more, we demonstrate the existence of antibodies against
G1 and G2 in infected rodents (Fig. 2 and Table 2). These
results differ from those obtained with immune sera from
the rodent Peromyscus maniculatus, in which no reactivity
against the Escherichia coli expressed G1 and G2 of Sin
Nombre virus could be detected (Yamada et al., 1995).
Among the 13 G epitopes identified in the present study,
seven are recognized commonly by human and rodent
immune sera. Furthermore, seven are predicted to be
highly accessible while four comprise predicted immuno-
genic regions (data not shown). In addition, five of these
epitopes are homologous to regions in PUUV and HTNV,
which have been associated by others (Heiskanen et al.,
1999; Ho¨rling and Lundkvist, 1997; Koch et al., 2003;
Wang et al., 1993) with the elicitation of neutralizing
antibodies (Table 2). For ANDV N we found eight
immunoreactive epitopes, of which five are recognizedTable 2
Average reactivity of human and rodent sera with peptides comprising the
structural proteins of ANDV
White squares indicate no reactivity (average scoring grade b0.5), gray
squares moderate reactivity (average scoring grade z0.5 and b1.5), and
black squares strong reactivity (average scoring grade z1.5). Epitope
regions marked in bold letters comprise amino acids homologous to regions
involved in the neutralization of HTNV (Koch et al., 2003; Wang et al.,
1993) and underlined epitopes include amino acids which are homologous
to regions recognized by HTNV non-neutralizing monoclonal antibodies
(Wang et al., 1993).by humans and mice (Table 2). Of these epitopes, two are
predicted to be highly accessible and two highly immuno-
genic (data not shown). The mayor antigenic determinants
of ANDV N are different between humans and rodents,
although both are located in the central region of the
protein (see Fig. 1 and Table 2). On the other hand it has
been reported that the mayor reactivity of immune sera to
recombinant N produced in E. coli is directed dominantly
to the amino terminal region (Go¨tt et al., 1997; Jenison et
al., 1994; Yamada et al., 1995).
The discrepancy of our results obtained with synthetic
peptides with data using recombinant truncated proteins
might be explained by the possibility that linear epitopes
might be hidden or not properly presented in E. coli
expressed proteins, situation also described by other
authors (Lundkvist et al., 1996). Since antibodies deve-
loped in infected individuals recognize mostly surface
structures of the native proteins, they may still react with
short linear peptides that represent only parts of a
conformational epitope (Davies et al., 1990). Hence,
immunoreactive regions recognized by sera with the
pepscan approach may contribute to the identification of
at least parts of sites for antibody binding, providing
valuable comprehension about the surface topology and
antigenicity of the structural proteins of ANDV. This
insight affords important information for the future design
of neutralizing monoclonal antibodies, a powerful tool in
the development of immunotherapies for the acute phase of
HCPS.Materials and methods
Patient and rodent sera
Sera samples from Chilean patients with confirmed
HCPS (n = 23) were provided by the Instituto de Salud
Pu´blica de Chile. Blood samples from naturally infected
rodents (n = 7) and negative controls were obtained from
Dr. Rebecca Aldunate from the Pontificia Universidad
Cato´lica. Human sera from healthy individuals used as
negative controls were obtained from the Hospital Salvador
of Santiago.
ELISA
Microtiter plate wells (Polysorb, Nunc, Rochester, USA)
were activated with 100 ng of recombinant nucleoprotein.
After 1 h incubation, the wells were blocked with 2% casein
sacarose for 1 h at 37 8C. Then 50 Al of sera in dilutions of
1:400 to 1:6400 was applied to the wells and incubated for
1.5 h at 22 8C. Each serum sample was tested in duplicate.
As second antibody 50 Al of goat anti-human IgG horse-
radish peroxidase (HRP) conjugate or goat anti-human IgM
HRP conjugate (KPL, Maryland, USA) was added in
1:2000 dilutions and incubated for 30 min at 22 8C. After
N.D. Tischler et al. / Virology 334 (2005) 319–326 325a 30-min incubation with 50 Al of tetramethylbenzidine
substrate (KPL, Maryland, USA), the reaction was stopped
by the addition of 50 Al 3 N H2SO4. The optical density was
measured at 450 nm.
Focus reduction neutralization assay (FRNT)
FRNT was performed as previously reported (Bharadwaj
et al., 2000). 4.5  104 Vero E6 cells were seeded into each
well of 48-well plates. The following day, 50–100 PFU of
ANDV strain CHI-7913 (Galeno et al., 2002) were
incubated with varying dilutions of heat-inactivated test
serum. After 1 h at 37 8C, the cell culture media were
replaced with the pre-incubated virus–serum mixture. After
4 h at 37 8C the virus and sera containing medium was
removed and substituted with fresh media containing 1.2%
methylcellulose. After 7 days the cells were fixed with
100% methanol containing 0.5% H2O2. Rabbit anti-nucle-
oprotein serum (1:5000) was added and incubated for 1 h at
37 8C. For detection, a goat anti-rabbit IgG (H + L) HRP
conjugate in a 1:1000 dilution (Jackson Immuno-Research,
West Grove, PA, USA) was added and after 1 h developed
with a DAB/metal concentrate substrate (Pierce, Rockford,
IL, USA). Finally, the number of viral foci were counted
under an inverted microscope.
Epitope mapping
Linear B-cell epitopes were identified by the use of the
pepscan method (Geysen et al., 1987). Peptides comprising
the whole nucleocapsid and glycoprotein precursor (GPC)
sequences of the Chilean isolate CHI-7913, GenBank
accession numbers AAO86636 and AY228238, respec-
tively (Tischler et al., 2003), were synthesized (Sigma-
Genosys, The Woodlands, USA). In total, 166 13-mers
peptides covalently linked to nitrocellulose membranes were
analyzed for their reactivity with sera samples as recom-
mended by the manufacturer instructions. Briefly, previ-
ously blocked membranes were incubated with sera in
dilutions of 1:200 to 1:1000 for 3 h at 22 8C. Second
antibodies conjugated to HRP were used in dilutions of
1:2000 to 1:5000 and incubated for 1 h at 22 8C. The
different second antibody conjugates were goat anti-human
polyvalent immunoglobulins (G, A, M) HRP conjugate
(Sigma, St. Louis, MO, USA) and goat anti-Peromyscus
leucopus IgG (H + L) conjugated to HRP (KPL, Maryland,
USA). Bound antibodies were detected with SuperSignal
Ultra (Pierce, Rockford, IL, USA) and chemiluminescence
measured by exposing the membranes 10–60 s to an X-ray
film. The reactivity was classified in three relative intensity
scales: no reactivity in white (grade 0), moderate reactivity
in gray (grade 1), and strong reactivity in black squares
(grade 2). A visible example of the grading of reactivity is
shown in Supplemental Fig. 1. Epitopes were defined as
immunodominant when the average score of human or mice
sera was zgrade 1.5.Prediction of accessible and antigenic regions
Protein side chains relative solvent accessibility was
predicted by the method of Mucchielli-Giorgi et al. (1999),
http://bioserv.rpbs.jussieu.fr. Antigenic regions were pre-
dicted utilizing the Vector NTI 8.0 (Welling et al., 1985).Acknowledgments
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